ArticleBiochimica et biophysica acta2012
Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS.
Article in Biochimica et biophysica acta, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 205 citations in OpenAlex.
- Randomized, double-blind, placebo-controlled study to evaluate the effect of treatment with an SPMs-enriched oil on chronic pain and inflammation, functionality, and quality of life in patients with symptomatic knee osteoarthritis: GAUDI study.Journal of translational medicine · 2023Trial
- Inhibition of neogenin fosters resolution of inflammation and tissue regeneration.The Journal of clinical investigation · 2018Trial
- Clinical Benefits of n-3 PUFA and ɤ-Linolenic Acid in Patients with Rheumatoid Arthritis.Nutrients · 2017Trial
- Trial
- Bioactive products formed in humans from fish oils.Journal of lipid research · 2015Trial
- Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation.Journal of lipid research · 2014Trial
- Plasma and aqueous humor levels of Maresin-1 in patients with diabetic retinopathy.Scientific reports · 2026Article
- Fatty Acid Metabolic Reprogramming in Rheumatoid Arthritis: Integrating Inflammation, Resolution Failure, and Joint Destruction.Journal of inflammation research · 2026Review
- Metabolomics: A Viable Approach to Understand the Pathogenesis of Reactive ArthritisEndocrine, metabolic & immune disorders drug targets · 2026Review
- Maresin-1 and maresin-2 as synovial fluid biomarkers in psoriatic, rheumatoid, and osteoarthritis.Frontiers in medicine · 2026Article
- Cerebrospinal fluid metabolomics reveals predictive biomarkers of nusinersen therapy efficacy in type II and type III spinal muscular atrophy patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Impact of the natural female reproductive aging on the rat serum lipidome.Clinical science (London, England : 1979) · 2025Article
- Platelet-derived microvesicles modulate the bioenergetic and inflammatory phenotype of human polymorphonuclear leukocytes.Journal of leukocyte biology · 2025Article
- AI-Assisted Plasmonic Diagnostics Platform for Osteoarthritis and Rheumatoid Arthritis With Biomarker Quantification Using Mathematical Models.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- IgA2 ACPA Drives a Hyper-Inflammatory Phenotype in Macrophages via ATP Synthase and COX2.European journal of immunology · 2025Article
- Comprehensive lipoprotein and glycoprotein characterization in rheumatoid arthritis plasma and association with clinical markers.Frontiers in molecular biosciences · 2025Article
- Development and Validation of a Cost-Effective Machine Learning Model for Screening Potential Rheumatoid Arthritis in Primary Healthcare Clinics.Journal of inflammation research · 2025Article
- Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to distinguish between spinal muscular atrophy type II and type III.CNS neuroscience & therapeutics · 2024Article
- High-mannose glycans fromFrontiers in immunology · 2024Article
- Exploring biomarkers associated with severity of knee osteoarthritis in Southern China using widely targeted metabolomics.BMC musculoskeletal disorders · 2023Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Human synovial fluid (SF) provides nutrition and lubrication to the articular cartilage. Particularly in arthritic diseases, SF is extensively accumulating in the synovial junction. During the last decade lipids have attracted considerable attention as their role in the development and resolution of diseases became increasingly recognized. Here, we describe a capillary LC-MS/MS screening platform that was used for the untargeted screening of lipids present in human SF of rheumatoid arthritis (RA) patients. Using this platform we give a detailed overview of the lipids and lipid-derived mediators present in the SF of RA patients. Almost 70 different lipid components from distinct lipid classes were identified and quantification was achieved for the lysophosphatidylcholine and phosphatidylcholine species. In addition, we describe a targeted LC-MS/MS lipid mediator metabolomics strategy for the detection, identification and quantification of maresin 1, lipoxin A(4) and resolvin D5 in SF from RA patients. Additionally, we present the identification of 5S,12S-diHETE as a major marker of lipoxygenase pathway interactions in the investigated SF samples. These results are the first to provide a comprehensive approach to the identification and profiling of lipids and lipid mediators present in SF and to describe the presence of key anti-inflammatory and pro-resolving lipid mediators identified in SF from RA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.